Xue‐Ning Yang

Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang et al. · Clinical Cancer Research · 2016 · 971 citations

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · The Lancet Oncology · 2017 · 520 citations

Medicine, Pathology, Gefitinib Versus Vinorelbine +8

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

Y.S. Li, Bo Jiang, Jin‐Ji Yang et al. · Annals of Oncology · 2018 · 328 citations · Full text

Cancer Research, Unique Genetic Profiles, Oncology +11

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Xu‐Chao Zhang, Shirley Zhang, Xue‐Ning Yang et al. · Molecular Cancer · 2010 · 298 citations · Full text

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · Journal of Clinical Oncology · 2020 · 261 citations · Full text